Anhui Fengyuan Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Anhui Fengyuan Pharmaceutical Co., Ltd. carries a market capitalization of 2.47B, placing it among publicly traded companies globally. Its enterprise value stands at 3.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.47B |
| Enterprise Value | 3.72B |
Share Statistics
Anhui Fengyuan Pharmaceutical Co., Ltd. currently has 464.77M shares outstanding.
| Shares Outstanding | 464.77M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Anhui Fengyuan Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 20.95. The price-to-sales ratio is 0.72, and the price-to-book ratio stands at 1.93.
| PE Ratio | 20.95 |
| PS Ratio | 0.72 |
| PB Ratio | 1.93 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | 14.08 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Anhui Fengyuan Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 19.87 and an EV/FCF ratio of 16.19. The EV/Sales ratio of 0.93 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.87 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.93 |
| EV / EBITDA | 19.87 |
| EV / EBIT | 19.87 |
| EV / FCF | 16.19 |
Financial Position
Anhui Fengyuan Pharmaceutical Co., Ltd. maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.92, indicating elevated leverage, while an interest coverage ratio of 5.94 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 0.89 |
| Quick Ratio | 0.08 |
| Debt / Equity | 47.92 |
| Debt / EBITDA | 5.42 |
| Interest Coverage | 5.94 |
Financial Efficiency
Anhui Fengyuan Pharmaceutical Co., Ltd. posts a return on equity of 9.48 and a return on invested capital of 5.15.
| Return on Equity (ROE) | 9.48 |
| Return on Assets (ROA) | 2.86 |
| Return on Invested Capital (ROIC) | 5.15 |
| Return on Capital Employed (ROCE) | 6.90 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.69 |
Taxes
Over the trailing twelve months, Anhui Fengyuan Pharmaceutical Co., Ltd. has paid 27.73M in income taxes, reflecting an effective tax rate of 17.16.
| Income Tax | 27.73M |
| Effective Tax Rate | 17.16 |
Stock Price Statistics
Anhui Fengyuan Pharmaceutical Co., Ltd.'s stock has declined approximately -19.54545% over the past 52 weeks. The 50-day moving average sits at 5.81, while the 200-day moving average is 6.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.54545% |
| 50-Day Moving Average | 5.81 |
| 200-Day Moving Average | 6.39 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Anhui Fengyuan Pharmaceutical Co., Ltd. generated 4.00B in revenue and converted that into 136.90M in net income, yielding earnings per share of 0.29. EBITDA reached 187.24M, while operating income came in at 187.24M.
| Revenue | 4.00B |
| Gross Profit | 793.87M |
| Operating Income | 187.24M |
| Pretax Income | 161.61M |
| Net Income | 136.90M |
| EBITDA | 187.24M |
| EBIT | 187.24M |
| Earnings Per Share (EPS) | 0.29 |
Balance Sheet
Anhui Fengyuan Pharmaceutical Co., Ltd. holds 188.23M in cash and equivalents against 1.02B in total debt, resulting in a net debt position of 593.97M. Total book value stands at 1.48B, with working capital of -239.57M providing operational flexibility.
| Cash & Cash Equivalents | 188.23M |
| Total Debt | 1.02B |
| Net Debt | 593.97M |
| Equity (Book Value) | 1.48B |
| Book Value Per Share | 3.19 |
| Working Capital | -239.57M |
Cash Flow
After subtracting -203.68M in capital expenditures, free cash flow totaled -203.68M - equivalent to -0.44 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -203.68M |
| Free Cash Flow | -203.68M |
| FCF Per Share | -0.44 |
Margins
Anhui Fengyuan Pharmaceutical Co., Ltd. operates with a gross margin of 19.83, reflecting its pricing power and cost economics. The operating margin of 4.68 and net profit margin of 3.42 provide insight into operational efficiency.
| Gross Margin | 19.83 |
| Operating Margin | 4.68 |
| Pretax Margin | 4.04 |
| Profit Margin | 3.42 |
| EBITDA Margin | 4.68 |
Dividends & Yields
The company's payout ratio of 53.83 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.15 |
| Dividend Yield | N/A |
| Payout Ratio | 53.83 |
| Shareholder Yield | -3.31 |
| FCF Yield | 7.10 |
Stock Splits
Anhui Fengyuan Pharmaceutical Co., Ltd.'s most recent stock split took place on June 7, 2024 with a 5:7 split ratio.
| Last Split Date | 6/7/2024 |
| Split Ratio | 5:7 |
Scores
Anhui Fengyuan Pharmaceutical Co., Ltd. posts an Altman Z-Score of 1.90, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.90 |